Payer Insights: RA [2016]: Bulletin 2 [Report Updated: 01062017] Prices from USD $1045

09:45 EDT 25 Jul 2017 | BioPortfolio Report Blog

This edition presents payer views on recent developments in the rheumatoid arthritis RA market. Topics include; recent positive opinion from the European Medicines Agency EMA for Regeneron/Sanofi's Kevzara sarilumab; recent approvals of biosimilar Enbrel and biosimilar Humira in the EU; and Eli Lilly/Incyte's Olumiant baricitinib gaining marketing authorisation in the EU.

Business Questions:

How do payers intend to cover sarilumab? Will there be any restrictions?
Is sarilumab likely to be utilised as a first or secondline therapy?
What factors will determine the incorporation of sarilumab in formularies? What role will drug pricing and treatment guidelines play?
Will biosimilars of Enbrel and Humira capture market share from branded antiTNFs?
Will the availability of biosimilar antiTNFs improve patient access to RA treatment?
What role will payers play in switching patients to biosimilar antiTNFs?
What patient subset will be targeted for switching to biosimilar antiTNFs?
On what factors will the uptake of biosimilars be dependent on?
Will payers prefer biosimilars of Enbrel over biosimilars of Humira?
How are biosimilars of Remicade viewed by payers?
Are payers surprised that baricitinib was declined approval in the US, but not in the EU?
How important will discounts on baricitinib be for making reimbursement decisions?
Will the RA treatment paradigm shift towards oral and/or biosimilar agents?

Original Article: Payer Insights: RA [2016]: Bulletin 2 [Report Updated: 01062017] Prices from USD $1045


More From BioPortfolio on "Payer Insights: RA [2016]: Bulletin 2 [Report Updated: 01062017] Prices from USD $1045"

Quick Search


Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...